Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples